SPRY 16.29 ARS Pharmaceuticals, Inc.
| Range: | 3.35-16.5 | Vol Avg: | 1093795 | Last Div: | 0 | Changes: | 0.61 |
| Beta: | 0.77 | Cap: | 1.41B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Dec 04 2020 | Empoloyees: | 23 | ||
| CUSIP: | CIK: | 0001671858 | ISIN: | US82835W1080 | Country: | US | |
| CEO: | Mr. Richard Lowenthal M.B.A., M.S., MSMSEL | Website: | https://ars-pharma.com | ||||
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow